ClinicalTrials.gg
CompletedNCT06853171Updated Aug 6, 2025

Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders

A Phase 1 interventional study of KarXT and KarX-EC in Psychiatric Disorders, sponsored by Bristol-Myers Squibb. Completed at 4 sites in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Study summary

This study is designed to assess the safety, tolerability, and pharmacokinetics (PK) of multiple doses and ratios of xanomeline and trospium chloride in an IR capsule (KarXT) and dual-burst release of xanomeline with immediate-release trospium chloride in adolescents with psychiatric disorders.

02

Conditions studied

  • Psychiatric Disorders

Browse trials for

03

In context

Mental Disorders

1,745 studies on the registry are indexed under Mental Disorders; 352 are open to participants now.

This study's enrollment of 24 is below the median of 100 across 1,304 interventional studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • LAR (ie, legal guardian or caregiver) must have signed and dated an IRB/IEC-approved ICF in accordance with regulatory, local, and institutional guidelines.
  • Confirmed , Fifth Edition, Text Revision (DSM-5-TR) psychiatric diagnosis of 1 of the following:

    1. Schizophrenia or schizoaffective disorder
    2. Bipolar I or II disorder
    3. Attention-deficit/hyperactivity disorder (ADHD)
    4. Tourette's disorder
    5. Autism spectrum disorder (ASD)
  • Participant is judged by the investigator to be clinically stable (eg, no psychiatric hospitalization within the last 6 months; no imminent risk of suicide or injury to self, others, or property).

Exclusion criteria

Exclusion Criteria:

  • Any neurological, metabolic (including type 1 diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, GI (including active obstructive GI disorders), carcinoma, active biliary disorders (eg, symptomatic gallstones) and/or urological disorder, congestive heart failure (uncontrolled), or CNS infection that would pose a risk to the participants if they were to participate in the study or that might confound the results of the study.
  • Participant has a risk for suicidal behavior during the study, as determined by the investigator's clinical judgment and C-SSRS.
  • \< 60 mL/min.
  • History of Gilbert's Disease or history of liver disease ( class A and higher).
  • History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma.
  • Participants with history of bladder stones or recurrent UTIs.
  • Other protocol defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Drug: KarXT

  • Experimental
    Cohort 2

    Drug: KarXT · Drug: KarX-EC

  • Experimental
    Cohort 3

    Drug: KarXT · Drug: KarX-EC

Interventions

  • DrugKarXT

    Drug pages: Xanomeline · Trospium

    Specified dose on specified days

    Also known as: Xanomeline and Trospium Chloride Capsule, BMS-986510

  • Specified dose on specified days

    Also known as: Xanomeline Enteric-coated, BMS-986519

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events (AEs)

    Time frame: Up to Day 43

  2. Number of participants with Serioues AEs (SAEs)

    Time frame: Up to Day 43

  3. Number of participants with AEs of Special Interest (AESIs)

    Time frame: Up to Day 43

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to Day 15

  2. Area under the concentration-time curve in 1 dosing interval (AUC(TAU))

    Time frame: Up to Day 15

  3. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))

    Time frame: Up to Day 15

  4. Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to Day 15

  5. Concentration at the end of a dosing interval (Ctau)

    Time frame: Up to Day 15

  6. Cmax accumulation index (AI_Cmax)

    Ratio of maximum observed plasma concentration at steady-state on Day 5 to maximum observed plasma concentration after first dose

    Time frame: Up to Day 15

  7. AUC accumulation index (AI_AUC)

    Ratio of area under the concentration-time curve in 1 dosing interval at steady-state on Day 5 to area under the concentration-time curve in 1 dosing interval after first dose

    Time frame: Up to Day 15

  8. Ctau accumulation index (AI_Ctau)

    Ratio of concentration at the end of the dosing interval at steady-state on Day 5 to maximum observed plasma concentration after first dose

    Time frame: Up to Day 15

  9. Average concentration within a dosing interval at steady-state (Css-avg)

    Time frame: Up to Day 15

  10. Apparent total body clearance (CLT/F)

    Time frame: Up to Day 15

  11. Effective elimination half-life during dosing interval (T-HALF(eff))

    Time frame: Up to Day 15

  12. T-HALFeff based on AUC observed (T-HALFeff_AUC)

    Effective elimination half-life based on degree of area under the plasma concentration-time curve accumulation observed

    Time frame: Up to Day 15

07

Study locations

4 sites
  • Local Institution - 0005
    Little Rock, Arkansas 72204, United States
  • Local Institution - 0006
    Orange, California 92868, United States
  • Local Institution - 0007
    Decatur, Georgia 30030, United States
  • Local Institution - 0008
    Overland Park, Kansas 66212, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Jul 2025, 2 months.

Of 27 phase 1 interventional studies under Mental Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 43. This study's 2 months is below that.

Mental Disorders covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Feb 28, 2025
StartActual
Apr 29, 2025
Primary completionActual
Jul 22, 2025
CompletionActual
Jul 22, 2025
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06853171
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
Apr 29, 2025
Primary completion
Jul 22, 2025
Completion
Jul 22, 2025
Last update
Aug 6, 2025

Study contacts

Bristol Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium

Start the discussion